Clinical Trials Logo

Gastrointestinal Tumors clinical trials

View clinical trials related to Gastrointestinal Tumors.

Filter by:

NCT ID: NCT06263205 Not yet recruiting - Pain, Postoperative Clinical Trials

Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques

Dressing
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to assess the effectiveness and safety of non-dressing (exposed wound) versus dressing techniques in postoperative wound management for patients with gastrointestinal tumors. The main questions it aims to answer are: 1. Does non-dressing of postoperative wounds in gastrointestinal tumor surgery provide equivalent or better wound healing compared to traditional dressing techniques? 2. Can non-dressing of postoperative wounds reduce patient pain and healthcare costs? Participants in this study, who are diagnosed with gastrointestinal tumors and undergoing surgery, will be randomly assigned to either the non-dressing group or the dressing group. The non-dressing group will have their surgical wounds left exposed after initial postoperative care, while the dressing group will receive regular wound dressing changes every 48-72 hours. Researchers will compare these two groups to see if there are differences in the rate of wound complications, pain levels, and overall healthcare costs. This study aims to provide evidence-based recommendations for postoperative wound care in gastrointestinal tumor surgeries, potentially improving patient outcomes and reducing medical expenses.

NCT ID: NCT06152757 Recruiting - Clinical trials for Gastrointestinal Tumors

BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors

Start date: October 9, 2023
Phase: Early Phase 1
Study type: Interventional

This study is an exploratory single-arm, open, modified "3+3" dose escalation study with BGT007H injection. Approximately 11 to 14 subjects with recurrent/refractory gastrointestinal tumors will be enrolled to evaluate the safety of BGT007H injection. Four dose levels were designed for this study: 1.0×10^8cells, 3.0×10^8cells, 1.0×10^9cells, and 3.0×10^9cells. The primary objective of this study was to evaluate the safety, tolerability and pharmacokinetic profile of BGT007H cell therapy in patients with recurrent/refractory digestive tract tumors, to determine the maximum tolerated dose or the best effective dose, and to initially evaluate the effectiveness of BGT007H cell products.

NCT ID: NCT06085365 Recruiting - Clinical trials for Gastrointestinal Tumors

Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors

Start date: July 24, 2023
Phase: Phase 3
Study type: Interventional

Evaluate the effects of Suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. The main endpoint of the study was the incidence of chemotherapy related adverse reactions (including bone marrow suppression, nausea and vomiting, diarrhea, and mucositis) in patients after two cycles of chemotherapy. The secondary endpoint indicators were: quality of life score (EORTC-QLQ-C30), nutritional risk score (PG-SGA, NRS2002), nutritional assessment indicators, changes in immune microenvironment, analysis of psychological status, survival time (1-year progression free survival rate), treatment tolerance (dose intensity, rate of treatment interruption, delay), etc.

NCT ID: NCT05981235 Recruiting - Clinical trials for Gastrointestinal Tumors

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Start date: December 14, 2023
Phase: Phase 1
Study type: Interventional

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.

NCT ID: NCT05922358 Not yet recruiting - Clinical trials for Gastrointestinal Tumors

Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

The incidence of oxaliplatin allergy reactions is between 12-15%, while the incidence of severe (grade 3-4) allergic reactions is between 0.5-2%. The purpose of this study is to prospectively investigate the incidence of oxaliplatin allergy and neurotoxicity, and to evaluate the use of effective anti-allergic and desensitization therapies to enable patients who are already allergic to oxaliplatin to complete their prescribed doses smoothly.

NCT ID: NCT05262335 Recruiting - Clinical trials for Gastrointestinal Tumors

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)

ALTER-G-001
Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with Unresectable Liver Metastases.

NCT ID: NCT04629326 Recruiting - Clinical trials for Gastrointestinal Tumors

PD-L1 Targeting Molecular Imaging of Solid Tumors

Start date: July 20, 2021
Phase: N/A
Study type: Interventional

The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.

NCT ID: NCT04171141 Terminated - Clinical trials for Gastrointestinal Tumors

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Start date: November 19, 2019
Phase: Phase 1
Study type: Interventional

A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors

NCT ID: NCT03833700 Active, not recruiting - Clinical trials for Colorectal Neoplasms

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Start date: March 5, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

NCT ID: NCT01768325 Completed - Clinical trials for Gastrointestinal Tumors.

Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core)

Start date: January 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate a new EUS-guided biopsy needle (ProCore®) comparing it to conventional EUS-TCB needle (Quick-Core®) in the diagnosis of your suspicious disorder. This study needle (ProCore®) is a new EUS-guided biopsy needle and has been recently approved by the U.S. Food and Drug Administration (FDA) for use.